Áttétes emlőrák: vizsgálatok itt: Brazília
17 of 18 trials · From ClinicalTrials.gov, checked 2026. november 18.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
- Where
- Barretos, Fortaleza, Goiânia, Londrina, Porto Alegre, Porto Velho, Recife, Salvador, São Paulo
- Életkor
- 18 év and over
- People
- 230 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT05894239 · EU 2022-502046-28-00 - 3. fázisTaking peoplePhase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- Where
- Belém, Belo Horizonte, Fortaleza, Goiânia, Natal, Porto Alegre, Rio de Janeiro, Salvador, São Caetano do Sul, São Paulo
- Életkor
- 18 év and over
- People
- 540 worldwide
- Run by
- Relay Therapeutics, Inc.
See details and how to joinNCT06982521 · EU 2025-523083-21-00 - 2/3. fázisTaking peopleRO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
- Where
- Brasília, Porto Alegre, Recife, São Carlos, São Paulo, Vitória
- Életkor
- 18 év and over
- People
- 650 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07413939 · EU 2025-524498-17-00 - 3. fázisTaking peopleA Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
- Where
- Alfenas, Barretos, Fortaleza, Goiânia, Londrina, Porto Alegre, Recife, Rio de Janeiro, Salvador, São Paulo, Teresina, Vitória
- Életkor
- 18 év and over
- People
- 450 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT06790693 · EU 2024-516162-11-00 - 3. fázisTaking peopleA Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- Where
- Barretos, Bequimão, Fortaleza, Goiânia, Lago Sul, Londrina, Mossoró, Natal, Porto Alegre, Rio de Janeiro, São Paulo
- Életkor
- 18 év and over
- People
- 800 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07174336 · EU 2025-522791-92-00 - 3. fázisTaking peopleA Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
- Where
- Lages, Natal, Porto Alegre, Recife, Santa Cruz do Sul, São Paulo
- Életkor
- 18 év and over
- People
- 1000 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07060807 · EU 2025-520582-51-00 - 2. fázisTaking peopleA Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
- Where
- Brasília, Curitiba, São Paulo, Vitória
- Életkor
- 18 év and over
- People
- 80 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07405801 · EU 2025-523013-28-00 - 3. fázisTaking peopleSaruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
- Where
- Cachoeira de Itapemirim, Curitiba, Fortaleza, Goiânia, Jaú, Porto Alegre, Ribeirão Preto, Salvador, São Paulo
- Életkor
- 18 év and over
- People
- 788 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06380751 · EU 2023-504180-16-00 - 3. fázisTaking peopleA Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
- Where
- Belo Horizonte, Brasília, Curitiba, Natal, Porto Alegre, Recife, Salvador, São José do Rio Preto, São Paulo, Teresina
- Életkor
- 18 év and over
- People
- 420 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT05646862 · EU 2022-502322-41-00 - 1/2. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Where
- Barretos, Florianópolis, Jaú, Porto Alegre
- Életkor
- 18 év and over
- People
- 680 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06330064 · EU 2023-509632-26-00 - 3. fázisTaking peopleA Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
- Where
- Ijuí, Lages, Londrina, Porto Alegre, São Caetano do Sul, São Paulo, Vitória
- Életkor
- 18 év and over
- People
- 400 worldwide
- Run by
- Pfizer
See details and how to joinNCT07062965 · EU 2025-520566-22-00 - 1. fázisTaking peopleBGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
- Where
- Barretos, Brasília, Caxias do Sul, Florianópolis, Natal, Porto Algre, Rio de Janeiro, Salvador, São Paulo
- Életkor
- 18 év and over
- People
- 433 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT06120283 · EU 2023-506888-34-00 - 3. fázisTaking peopleA Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
- Where
- Porto Alegre, Santa Cruz do Sul, São Paulo, Taubaté, Teresina
- Életkor
- 18 év and over
- People
- 1200 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06312176 · EU 2023-504918-29-00 - 1. fázisTaking peopleOpen-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- Where
- Natal, Porto Alegre, São Paulo, Sorocaba
- Életkor
- 18 év and over
- People
- 392 worldwide
- Run by
- TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
See details and how to joinNCT06625775 · EU 2024-519445-29-00 - 3. fázisNot yet taking people in BrazíliaElacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
- Where
- Bento Gonçalves, Cachoeiro de Itapemirim, Itajaí, Porto Alegre, Salvador
- Életkor
- 18 év and over
- People
- 300 worldwide
- Run by
- MedSIR
See details and how to joinNCT06382948 · EU 2024-512926-27-00 - 3. fázisTaking peopleTrastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
- Where
- Brasília, Curitiba, Florianópolis, Ijuí, Jaú, Londrina, Riberão Preto, Rio Grande, Salvador, Santa Catarina, Santo André, São José do Rio Preto, São Paulo
- Életkor
- 18 év and over
- People
- 250 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT05950945 · EU 2023-505616-38-00 - No phaseNot yet taking people in BrazíliaExercise Training in Women With Metastatic Breast Cancer
- Where
- Londrina
- Életkor
- 18 év and over
- People
- 78
- Run by
- State University of Londrina
See details and how to joinNCT07521826